Non-inferiority comparisons (YF PPS and PPS).
dengue, yellow fever
DENGUE, VIRUS, YELLOW FEVER, SECONDARY
Bold indicates non-inferiority criteria metDENV, dengue virus; GMT, geometric mean titer; P, placebo; PPS, per-protocol set; SR, seroprotection rate; TAK-003, tetravalent dengue vaccine candidate; YF-17D, live attenuated yellow fever vaccineFor the primary immunogenicity endpoint, non-inferiority (NI) was concluded if the upper bound of the 95% CI of the difference in YF seroprotection rates (Group 1 minus Group 3) at Month 1 was <5%.For the secondary objectives, NI of YF GMTs when YF-17D was concomitantly administered with TAK-003 versus placebo was concluded if the upper bound of the 95% CI for the GMT ratio (Group 1/Group 3) was <2. NI of DENV GMTs when TAK-003 was concomitantly administered with YF-17D versus placebo was concluded if the upper bound of the 95% CI for the GMT ratio (Group 2/Group 3) was <2.n represents the number of participants with data evaluated